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OBSERVATION OF PERSISTENCE RATES AND POTENTIAL COST SAVINGS
ASSOCIATED WITH CERTOLIZUMAB PEGOL TREATMENT FOR RHEUMATOID
ARTHRITIS IN ENGLAND, WALES AND NORTHERN IRELAND CLINICAL
PRACTICE
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OBJECTIVES: In the UK, access to anti-TNF therapies for the treatment of rheuma-
toid arthritis (RA) is standardized by National Institute for Clinical Excellence guid-
ance. Certolizumab pegol (CZP) studies in RA demonstrate that patient response to
therapy at 12 weeks predicts clinical outcome at 1 year. In the UK, CZP is available
via a Patient Access Scheme (PAS), providing CZP free for the first 12 weeks. This
analysis examines persistency and potential cost savings realised with a 12 week
CZP decision. METHODS: A retrospective analysis examined 2,744 patients receiv-
ing CZP between March 2010 and March 2012 from Healthcare at Home, a UK home
health care service provider. Persistence was defined as patients (%) continuing to
receive CZP deliveries, calculated at specific time points. Treatment start was first
delivery date and patients were censored according to this. A simple cost analysis
was performed. RESULTS: At 13, 26, 39 and 52 weeks, persistence rates were 93%,
79%, 70% and 65% in naive (no prior anti-TNF) and 88%, 68%, 56% and 48% in switch
(1 prior anti-TNF) patients respectively. Analyzing first-line biologic drug costs
only, the NHS would save £2,363.14/patient in the first year if CZP were used instead
of adalimumab (assuming similar persistence); largely due to the PAS. Stopping
treatment for non-responders at Week 12 (CZP) vs Week 24 (adalimumab), could
allow the UK NHS to re-invest £ 2145/patient. CONCLUSIONS: In this UK cohort,
CZP persistence was higher in naive pts. Reinforcing a 12 week treatment decision
could result in more efficient spend on drugs and rapid initiation of alternative
treatment in non-responders.
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PALIPERIDONE PALMITATE LONG-ACTING INJECTION FOR BRAZILIAN NON-
ADHERENT SCHIZOPHRENIC PATIENTS: 5-YEAR BUDGET IMPACT ANALYSIS
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OBJECTIVES: To estimate the budget impact of PP-LAI in treating chronic schizo-
phrenia in Brazil from the perspective of the public payer, specifically for patients
with adherence issues. METHODS: The budget impact model (BIM) was used to
estimate eligible population and to project investments for the first 5y (2012-2016).
An approach based on prevalence and adherence rates reported by previous stud-
ies was employed to define the eligible population. Two scenarios were simulated:
1) the current setting, in which schizophrenic patients with adherence issues re-
ceive atypical drugs already provided by the Brazilian Public Healthcare System
(BPHS) (olanzapine, quetiapine and ziprasidone), and 2) the proposed setting, in
which patients presenting non-adherence behaviors on oral atypical therapy can
receive PP-LAI. Final costs were calculated considering drug acquisition costs and
health resource consumption related to outpatient follow-up, hospitalizations and
adverse events. RESULTS: The BIM estimated the population eligible for PP-LAI
ranging from 2,207 patients (2012) to 2,271 patients (2016), approximately 0.3% of
the projected schizophrenia population attending BPHS services. With all drugs tax
exempted, the acquisition costs were: PP-LAI 5,566BRL (1st year) and 4,963BRL (sub-
sequent years); olanzapine 3,850BRL; quetiapine 5,416BRL; ziprasidone 1,474BRL.
The model estimated the current BPHS expenses at 287 million BRL in 2012, reach-
ing 296 million BRL in 2016. If PP-LAI is included in the reimbursement list, the
yearly budget impact in 2012 would be 2.4 million (0.83%) and 1.1 million in 2016
(0.37%). The cumulative budget impact would reach 6,658,573BRL in 5 years.
CONCLUSIONS: PP-LAI is an effective therapeutic option for schizophrenic pa-
tients, particularly those who would benefit from LAI antipsychotic drugs. In this
BIM, the investments to include PP-LAI on BPHS reimbursement lists were esti-
mated to be BRL 6.7 million in five years (an increment of 0.46% in the current
budget).
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ADEQUATE ADHERENCE TO INTRANASAL CORTICOSTEROIDS IS ASSOCIATED
WITH SIGNIFICANTLY REDUCED NUMBER AND COSTS OF OUTPATIENT VISITS
AMONG PATIENTS NEWLY DIAGNOSED WITH ALLERGIC RHINITIS
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OBJECTIVES:To examine the influence of intranasal corticosteroid (INS) adherence
on 18-month outpatient use and costs among patients newly diagnosed with aller-
gic rhinitis (AR). METHODS: This was a 12-year (6/1997-7/2009) retrospective
matched cohort study in United States (U.S.) Florida Medicaid enrollees with newly
diagnosed AR (1 year preceding initial AR diagnosis without any claim for ICD-9
477.0, 477.8, 477.9). Selected were patients receiving 1 INS fill after their initial AR
diagnosis with sufficient data (1 year of data before and 3 years of data after
index INS fill) for analysis. “Adequate” adherence was defined as an INS medication
possession ratio (MPR; calculated as the total days of supply during 18 months)
70% following patient’s index INS fill, and inadequate adherence as MPR 70%.
Patients with adequate INS adherence (Adequate-INS) were matched 1:3 to those
with inadequate adherence (Inadequate-INS) on age at initial AR diagnosis; sex;
race/ethnicity; and Charlson Comorbidity Index and comorbid atopic illness
(asthma, atopic dermatitis, and conjunctivitis) 1 year before index INS fill. Wil-
coxon signed-rank tests compared median outpatient use and costs (in U.S. dollars;
USD) between Adequate-INS and Inadequate-INS groups over 18 months.
RESULTS: Among all enrollees (N7,524,231), 75,337 patients aged 12 years were
newly diagnosed with AR. Of these, 343 Adequate-INS patients were matched to
698 Inadequate-INS patients. Demographics and comorbid illness rates did not
significantly differ between groups at baseline. Median 18-month number of out-
patient visits (19.0 versus 25.0, p0.0001) and costs ($1,633 versus $2,552 in USD,
p0.0001) were significantly lower among Adequate-INS versus Inadequate-INS
patients. CONCLUSIONS: Significant differences between adherence groups in
number and costs of outpatient visits were observed over 18 months following INS
initiation among these U.S. patients receiving State Medicaid Health care coverage.
Results suggest that INS adherence may play a role in improving health outcomes
of patients with AR.
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OBJECTIVES: To develop a comprehensive model to estimate health and cost out-
comes associated with different therapeutic options in major depressive disorder
(MDD), accounting for long-term clinical events and treatment pathways.
METHODS: A discrete event simulation (DES) model was developed with a flexible
time horizon. This model simulated short- and long-term clinical events (partial
response, remission, relapse, recovery, recurrence), adverse events, and treatment
changes (titration, switch, addition, discontinuation) in a cohort of MDD patients.
Patient characteristics influencing clinical evolution were considered (e.g., residual
symptoms). The model was tested using fictitious antidepressants with three lev-
els of efficacy, tolerability and drug cost (low, medium, high) from first-line to
third-line. In the base case analysis, a medium-profile antidepressant was used
first-line, and profiles of subsequent treatment lines depended on reason for
switch (lack of efficacy or low tolerability). Input data were derived from the liter-
ature. Model outputs included time by clinical state, QALYs and costs. Costs were
estimated for the UK, from payer and societal perspectives. One-way sensitivity
analyses were performed. This model will be provided open source so that all
interested researchers can contribute by incorporating new features or adding
input data. RESULTS: Predicted costs and QALYs from this model are within the
range of results from previous economic evaluations. The largest cost components
from payer perspective were physician visits and hospitalisations. Key parameters
driving the predicted costs and QALYs were utility values, effectiveness and fre-
quency of physician visits. Differences in QALYs and costs between two strategies
with different effectiveness increased approximately two-fold when the time ho-
rizon increased from 1 to 5 years. CONCLUSIONS: This DES model can provide a
more comprehensive evaluation of different therapeutic options in MDD, com-
pared to existing Markov models and can be used to compare a wide range of health
care technologies in various groups of MDD patients.
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ADJUVANT BREAST CANCER THERAPIES
Frederix GW1, Van hasselt JG2, Schellens JH3, Hövels AM4, Huitema AD5, Raaijmakers
JA6, Severens J7
1Netherlands Cancer Institute, Amsterdam, The Netherlands, 2Slotervaart Hospital &
Netherlands Cancer Institute, Amsterdam, The Netherlands, 3Netherlands Cancer Institute &
Utrecht University, Amsterdam, The Netherlands, 4Utrecht University, Utrecht, The Netherlands,
5Slotervaart Hospital/Netherlands Cancer Institute, Amsterdam, The Netherlands, 6Utrecht
University & GlaxoSmithKline, Utrecht, The Netherlands, 7Erasmus University Rotterdam, The
Netherlands
OBJECTIVES: Markov models developed for cost-effectiveness analysis (CEAs)
often contain differences in model structure due to differences in assumptions.
Such differences may lead to differences in outcome and can therefore impact
decision making. The objective of this analysis was to identify structural as-
sumptions, reported for CEAs comparing the cost-effectiveness of tamoxifen
and anastrazole for adjuvant breast cancer therapy, and to subsequently eval-
uate the impact of these assumptions, both individually as well as combined, on
analysis outcome measures. METHODS: Based on a literature review of available
published Markov model based CEAs comparing tamoxifen and anastrazole, struc-
tural model assumptions were identified. Subsequently, a base case model was
defined and built in R, representing the fundamental structure present in all iden-
tified CEAs from literature. Subsequently, different structural model components
as identified from the published CEAs, were added to the base case model sepa-
rately, as well as simultaneously. Outcome measures Life Years gained (LYG) and
incremental costs were calculated for each of these models. RESULTS: The base
case model outcome demonstrated a gain of 0.263 LYG for anastrazole compared to
tamoxifen with an ICER of €13.868/LYG. The separate impact of assumptions on
LYG, ranged from 0.207 to 0.356, while ICERs ranged from €9804/LYG to €17.966/
LYG. For the comparison of combined assumptions as present in identified CEA’s,
LYs gained ranged even from 0.207 to 0.383 with ICERs ranging from €9683/LYG to
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€17.570/LYG. CONCLUSIONS: It was possible to develop a unique base case
Markov model for early breast cancer from the literature and to adjust this
model taking various published assumptions into account. The adaptation of
various assumptions resulted in differences in outcomes of CEAs of adjuvant
breast cancer therapies. This case example demonstrates the importance of the
development of standardized model structures for adjuvant breast cancer ther-
apies.
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OBJECTIVES: Breast cancer is the most common malignant disease in Western
women. In the ONCOTYROL research center, a Breast Cancer Outcomes & Policy
(ONCOTYROL) model was developed to evaluate the cost-effectiveness of the
new 21-gene assay that supports personalized decisions on adjuvant chemo-
therapy. The goal of this study was to validate our Oncotyrol-model. METHODS:
The 21-gene assay was evaluated by simulating a hypothetical cohort of 50-year
old women over a lifetime time horizon using a discrete event simulation. Main
model outcomes were life-years gained, quality-adjusted life-years (QALYs) and
costs. Based on the new ISPOR-SMDM best practice recommendations, the
model has been validated. Major focus was on our experiences of the cross
validation, i.e. the comparison of modeling results between the discrete-event-
simulation ONCOTYROL-model and the THETA-model (Toronto Health Eco-
nomics and Technology Assessment Collaborative) which is a Markov model.
Therefore, the Oncotyrol-model has been populated with the Canadian THETA-
model parameters. Cross validation started with a comparison of the natural
history followed by QALYs and costs. RESULTS: The relative differences varied
among the model outcomes. The smallest differences we found for costs, the high-
est for QALYs. All differences were smaller than 2.5%. The comparison of the effi-
ciency frontiers showed that small differences due to the modeling approach can
lead to a different set of non-dominated test-treatment strategies. The cross model
validation involved several challenges: distinguishing between outcomes differ-
ences due to different modeling techniques and errors, definitions for meaningful
differences and comparison techniques (mean estimates, distributions, multivar-
iate outcomes). CONCLUSIONS: Cross-model validation was crucial to identify and
correct modeling errors and to explain remaining differences of modeling results.
However, small differences can lead to relevant changes in cost-effectiveness re-
sults.
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OBJECTIVES: Compliance and treatment duration can have a significant impact
on costs and health outcomes in health-economic assessments, especially in
high-cost therapy areas such as oncology. The objective of this study was to
systematically review different methods for addressing treatment compliance
and discontinuation in oncology economic models, critique the identified meth-
odologies, and highlight best practices. METHODS: A systematic review was un-
dertaken to investigate the different methods that could be used to include com-
pliance and treatment discontinuation in economic modelling in oncology
populations. MEDLINE, Embase, EconLit and the Cochrane Library (from 2000 on-
wards), and technology assessment documents and manufacturer submissions to
the National Institute for Health and Clinical Excellence (NICE) were searched for
economic analyses which mentioned compliance or discontinuation. Results were
filtered using pre-specified selection criteria and data extracted into a pre-defined
template. RESULTS: Sixty-eight publications of 51 models were included, compris-
ing 20 journal publications and 48 technology appraisal documents. Possible meth-
ods were divided into ten categories. Seven studies mentioned discontinuations,
but did not include a modelling approach. There was a lack of consensus regarding
the methods applied. Twenty studies varied dose or discontinuation rate in sensi-
tivity analyses, although impact on overall outcomes was rarely explored. Dose
intensity was most often adopted from clinical trials. Effects on the overall out-
comes by inclusion of discontinuations or dose intensity adjustments were rarely
discussed. Overall, the authors of included publications poorly justified their meth-
ods regarding compliance assumptions. CONCLUSIONS: The combination of sev-
eral methods could improve accuracy of modelling discontinuations. Discontinu-
ations should affect three aspects of the model: transition probabilities, costs and
effects. Clear explanations and justification of the included parameter assump-
tions should also be improved in NICE submissions to enhance likelihood of posi-
tive recommendation. Standardised guidelines could raise more attention to com-
pliance in economic modelling and could improve the accuracy of economic
models.
PODIUM SESSION II:
PATIENT HEALTH CARE ACCESS
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ASSESSING THE PROGRESSION OF THE UK NHS HEALTH CARE REFORMS AND
THE IMPACT ON HEALTH CARE DELIVERY
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OBJECTIVES: The UK NHS is currently undergoing the most significant reforms to
its structure possibly since the NHS was formed. There are many questions at all
levels regarding the reforms, and this research aimed to address some of them The
objectives were – 1) To assess how the reforms were proceeding and what issues
they had been encountered, and 2) To determine how the delivery of care has been
impacted at a grassroots level.METHODS:We adopted a two phased approach. The
first phase involved extensive literature review in order to assess how the reforms
were expected to proceed, what the outcomes were likely/expected to be and when
key milestones were expected to be met. The second phase was centred on primary
research carried out by Double Helix personnel. Key stakeholders in the reforming
NHS at all levels were approached and data was collected using a combination of
qualitative and quantitative methodologies. RESULTS:While the vision of the NHS
reforms was very clear from the outset, the actual progression on the ground has
been met with considerable challenges. Even while CCGs in the first wave were in
the process of undergoing assessment, changes to the overall architecture of the
reforms were continuous. Key personnel at all levels lacked a clear grasp of what
the following 12 months would bring, and various influencer and guideline bodies
faced uncertain futures or lacked a clear remit. At the stage of writing there was no
clear evidence either way to suggest that the reforms were having an impact on
frontline health care delivery. CONCLUSIONS: The UK NHS Reforms were always
going to be challenging due to their scale and complexity. However there has been
a clear lack of direction at various levels leading to uncertainty and fears for the
short and medium term future.
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OBJECTIVES: Early development of HTA in Italy has been mainly hospital-based
(HB HTA). HB HTA can support administrative procedures increasing transparency
and promoting the bottom-up awareness around HTA principles. Whether HTA
has an impact on actual hospital expenditure and consumption of health technol-
ogies, particularly medical devices (MDs), has not been investigated. This research
aimed at exploring potential HB HTA’s impact on purchased MDs, once assessed its
diffusion in Italy. METHODS: We run a survey, based on a semi structured on line
questionnaire, on a sample of Italian Healthcare trusts, asking for 2008-2009 data
about consumption and unitary costs of a class of MDs (e.g. coronary stents) and
HTA activities. HB HTA’s activities have been surveyed in terms of diffusion and
structural/organizational characteristics. We assessed in a multivariate analysis
whether an association exists between the implementation of HTA activities and
MDs diffusion at the local level. RESULTS: Given 46 respondents, located in 15
Italian Regions, 22 (48%) have a commission for MDs. Commissions meet almost
monthly and encompass on average 10 members (SD5.4). On average there are 2
pharmacists (SD1.13); 3 medical doctors (SD2.91) and 1 clinical engineer
(SD2.9). About 60% of the Commissions produce evaluation forms and repertory,
whereas about 40% produce hospital guidelines and other documents to support
procurement activities. A preliminary analysis of HB HTA’s characteristics shows
that the perception on the importance of HTA in a hospital may depend on the
presence/absence of the organizational structure (such as defined HTA Commis-
sion) and a correlation exists between expenditures/volumes of coronary stents
and level of importance of “economic” aspects in HTA. CONCLUSIONS:We suggest
HTA could potentially impact on health technologies’ uptake and expenditure
when realized within the hospital setting, stimulating collaboration between dif-
ferent units and actors, thus providing local health care managers with a useful
tool for budget control and planning.
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OBJECTIVES: Cataract surgery is commonly performed in developed countries.
Artificial lens implantation is considered to be one of the most cost-effective med-
ical interventions. The aim of this analysis was to describe the organization of
cataract surgery in Poland and compare access and quality of care with other
countries. METHODS: Access to cataract surgeries was assessed on the base of
statistical reports issued by National Health Fund (NHF) regarding number and
structure of cataract surgeries and waiting times. Epidemiological data was used to
estimate number of patients qualifying for treatment. Data on reimbursement was
obtained from Ministry of Health and NHF. To supplement publicly available data,
a number of clinical experts were consulted. RESULTS: Each year 170k cataract
surgeries are reimbursed in Poland. 300k patients are currently in a queue for
surgery. The mean waiting time is geographically dependent and varies from 8 up
to 22 months (stable cases). There is a high disproportion among voivodeships in
funding of cataract surgeries. The Cataract Surgery Rate (CSR) in 2011 was 4.4k
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